Interview

Page of ( Articles)

Cochlear's Anthony Bishop on the impact of a ‘humbling’ experience December 19, 2019
Anthony Bishop, who leads Cochlear in the Asia Pacific region, says one of the most impactful parts of his job is the ‘humbling’ experience of meeting the families of profoundly deaf children who are able to hear for the first time.
Mark Glover: The tech opportunity for clinical trials November 14, 2019
Medidata's Mark Glover told BiotechDispatch the technology-focused clinical research organisation is developing options like the 'synthetic control arm' to address the challenge of recruiting patients for trials targeting rare diseases.
Dr John Bashford: Redefining the future for rare cancers July 9, 2019
Dr John Bashford, research director at the Icon Group, spoke with BiotechDispatch about its approach to cancer care and clinical trials using targeted therapy and immunotherapy.
'Extending' the 'promise of immunotherapy' March 21, 2019
MSD invests almost $400 million every year in Australian clinical trials, the majority involving PBS-listed immunotherapy KEYTRUDA, according to the company's Dr Bilal Piperdi.
'Our current concept of aging is wrong' March 12, 2019
Two Australians are at the helm of a US-based company looking to revolutionise the health system's approach to and treatment of aging.
New testing means patients no longer 'defined by their symptoms' February 28, 2019
AbbVie's head of global head of immunology discovery research says the ability to profile patients at the molecular level has the potential to dramatically change treatment for people living with chronic conditions.
AusBiotech CEO Lorraine Chiroiu on early impressions and future priorities September 3, 2018
Recently appointed CEO of AusBiotech, Lorraine Chiroiu, says the association plans to build its role in policy to help ensure the operating environment supports the continued growth of the sector.
Driven by the 'profound unmet needs of patients' August 7, 2018
Biogen's global chief medical officer told BiotechDispatch the company is undaunted by the historically high failure rates in the development of treatments for Alzheimer’s.
A 'disruptive technology' that 'changed everything' June 26, 2018
Whole genome sequencing is already changing healthcare systems and treatments, according to Dr Howard Jacob, vice president and head of genomic research at AbbVie.
Value-based healthcare 'inevitable' April 12, 2018
A move to value-based healthcare is inevitable, says the global CEO of Medtronic Omar Ishrak. Mr Ishrak spoke with BiotechDispatch during a recent trip to Australia....
New research centre in Queensland October 18, 2016
The University of Queensland has launched a new $7 million regenerative medicine research centre with the aim of improving the quality of life of senior Australians. Queensland Premier...
Australia must do more to build 'true innovation eco-system' May 30, 2016
Teva Pharma is the world's largest generics company but there is much more to Teva in Australia, according to managing director John Michailidis. Mr Michailidis was appointed to lead...

Page of ( Articles)

Interview

Most Read

MTPConnect appoints experienced industry and R&D executive

AusBiotech seeks industry’s views and policy priorities

Data on PAT-DX1 to be presented at international summit

European approval for QBiotics tigilanol tiglate

China backs stronger biopharma IP in US trade deal

New Stories

New leadership for the Department of Health

PolyNovo announces European shipments of NovoSorb BTM

New director for BARD1 Life Sciences

Admedus announces new trial of ADAPT as surgical aortic valve replacement

Global regenerative medicine industry poised for continued expansion

MTPConnect appoints experienced industry and R&D executive

AusBiotech seeks industry’s views and policy priorities

Sign In

Most Read

MTPConnect appoints experienced industry and R&D executive

AusBiotech seeks industry’s views and policy priorities

Data on PAT-DX1 to be presented at international summit

European approval for QBiotics tigilanol tiglate

China backs stronger biopharma IP in US trade deal

Follow Us

New Stories

New leadership for the Department of Health

PolyNovo announces European shipments of NovoSorb BTM

New director for BARD1 Life Sciences

Admedus announces new trial of ADAPT as surgical aortic valve replacement

Global regenerative medicine industry poised for continued expansion

MTPConnect appoints experienced industry and R&D executive

AusBiotech seeks industry’s views and policy priorities